latest development

News & Events

We have reported several times on Vidac Pharma plc in recent weeks. The interest in the share is enormous for a penny stock, with over 200,000 shares changing hands at times. The Company has just announced that the US Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent application to protect a group of molecules. These molecules can trigger an immune response in various cancers by detaching the enzyme hexokinase-2 (HK2) from the mitochondrial VDAC pores. The molecules are the key compounds in Vidac's two drug candidates, VDA-1102 and VDA-1275.

For more detailed information, please visit